Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Related: The FDA Is Investigating Reports of These Serious Side Effects from Weight Loss Drugs NAION is a rare eye condition that mainly affects people over the age of 50. The main symptom of ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

was linked to a higher risk of a rare eye condition known as "eye stroke," or non-arteritic anterior ischemic optic neuropathy (NAION). This condition can lead to sudden vision loss. Building on these ...

Semaglutide, a GLP-1 receptor agonist, is approved for obesity and type 2 diabetes treatment in Europe and the US. The studies suggest semaglutide use may more than double the likelihood of developing ...

The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...

HealthDay News — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...

While untreated diabetes can cause various eye complications, these are generally less severe but more common than the optic nerve damage associated with NAION. Lead author Anton Pottegård ...

TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, ...